Last reviewed · How we verify
NCT03714984
The Efficacy of Pre-operative Educational Pelvic Floor Intervention on Urinary Continence
NA trial testing Pre operative exercise in Prostatectomy in 120 participants. Completed in 4 December 2023.
4 December 2019
Quick facts
| Lead sponsor | European Institute of Oncology |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 120 |
| Start date | 15 October 2018 |
| Primary completion | 4 December 2019 |
| Estimated completion | 4 December 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Pre operative exercise
- Control Group — full drug profile →
Conditions studied
- Prostatectomy — all drugs for Prostatectomy →
- Pelvic Floor Disorders — all drugs for Pelvic Floor Disorders →
Sponsor
European Institute of Oncology
Who can join
Adults 40 to 70, male only, with Prostatectomy or Pelvic Floor Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prostate cancer is the most common type of cancer between male population and urinary incontinence (UI) is the most common of long-term sequelae. Nowadays, robotic prostatectomy became the surgery standard but there is still discrepant results regards the incidence of UI and there is a lack of studies about the use of pelvic floor rehabilitation in this population. Our study aims to assesses the efficacy of preoperative educational method in urinary incontinence after robotic prostatectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03714984
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatectomy
Currently open trials in the same condition.
- NCT06274047 — PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life i · Phase 3 · recruiting
- NCT06982469 — High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy · recruiting
- NCT03080116 — Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy · Phase 2 · active not recruiting
Other European Institute of Oncology trials
Trials by the same sponsor.
- NCT07374809 — IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER · NA · not yet recruiting
- NCT07429851 — CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07508319 — Role of the Immune System in Preventing Laryngeal Cancer · recruiting
- NCT07180693 — Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03714984 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by European Institute of Oncology
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03714984.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing